The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Neoantigen Cancer Vaccine Market Research Report 2024
Synopsis
It is through the use of tumor cell-associated antigens to awaken the body's immune system against cancer.
The global Neoantigen Cancer Vaccine market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Neoantigen Cancer Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neoantigen Cancer Vaccine.
Report Scope
The Neoantigen Cancer Vaccine market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Neoantigen Cancer Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Neoantigen Cancer Vaccine companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche
Medimmune
Merck
Advaxis
Agenus
Genocea
Gritstone Oncology
Neon Therapeutics
Nouscom
OSE Immunotherapeutics
Medigene
Vaccibody
Brightpath Biotherapeutics
Geneos Therapeutics
Segment by Type
Personalized Vaccine
Off-the-shelf Neovaccines
Segment by Application
Hospital
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Neoantigen Cancer Vaccine companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
It is through the use of tumor cell-associated antigens to awaken the body's immune system against cancer.
The global Neoantigen Cancer Vaccine market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Neoantigen Cancer Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neoantigen Cancer Vaccine.
Report Scope
The Neoantigen Cancer Vaccine market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Neoantigen Cancer Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Neoantigen Cancer Vaccine companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche
Medimmune
Merck
Advaxis
Agenus
Genocea
Gritstone Oncology
Neon Therapeutics
Nouscom
OSE Immunotherapeutics
Medigene
Vaccibody
Brightpath Biotherapeutics
Geneos Therapeutics
Segment by Type
Personalized Vaccine
Off-the-shelf Neovaccines
Segment by Application
Hospital
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Neoantigen Cancer Vaccine companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neoantigen Cancer Vaccine Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Personalized Vaccine
1.2.3 Off-the-shelf Neovaccines
1.3 Market by Application
1.3.1 Global Neoantigen Cancer Vaccine Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Neoantigen Cancer Vaccine Market Perspective (2019-2030)
2.2 Neoantigen Cancer Vaccine Growth Trends by Region
2.2.1 Global Neoantigen Cancer Vaccine Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Neoantigen Cancer Vaccine Historic Market Size by Region (2019-2024)
2.2.3 Neoantigen Cancer Vaccine Forecasted Market Size by Region (2025-2030)
2.3 Neoantigen Cancer Vaccine Market Dynamics
2.3.1 Neoantigen Cancer Vaccine Industry Trends
2.3.2 Neoantigen Cancer Vaccine Market Drivers
2.3.3 Neoantigen Cancer Vaccine Market Challenges
2.3.4 Neoantigen Cancer Vaccine Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Neoantigen Cancer Vaccine Players by Revenue
3.1.1 Global Top Neoantigen Cancer Vaccine Players by Revenue (2019-2024)
3.1.2 Global Neoantigen Cancer Vaccine Revenue Market Share by Players (2019-2024)
3.2 Global Neoantigen Cancer Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Neoantigen Cancer Vaccine Revenue
3.4 Global Neoantigen Cancer Vaccine Market Concentration Ratio
3.4.1 Global Neoantigen Cancer Vaccine Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neoantigen Cancer Vaccine Revenue in 2023
3.5 Neoantigen Cancer Vaccine Key Players Head office and Area Served
3.6 Key Players Neoantigen Cancer Vaccine Product Solution and Service
3.7 Date of Enter into Neoantigen Cancer Vaccine Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Neoantigen Cancer Vaccine Breakdown Data by Type
4.1 Global Neoantigen Cancer Vaccine Historic Market Size by Type (2019-2024)
4.2 Global Neoantigen Cancer Vaccine Forecasted Market Size by Type (2025-2030)
5 Neoantigen Cancer Vaccine Breakdown Data by Application
5.1 Global Neoantigen Cancer Vaccine Historic Market Size by Application (2019-2024)
5.2 Global Neoantigen Cancer Vaccine Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Neoantigen Cancer Vaccine Market Size (2019-2030)
6.2 North America Neoantigen Cancer Vaccine Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Neoantigen Cancer Vaccine Market Size by Country (2019-2024)
6.4 North America Neoantigen Cancer Vaccine Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Neoantigen Cancer Vaccine Market Size (2019-2030)
7.2 Europe Neoantigen Cancer Vaccine Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Neoantigen Cancer Vaccine Market Size by Country (2019-2024)
7.4 Europe Neoantigen Cancer Vaccine Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Neoantigen Cancer Vaccine Market Size (2019-2030)
8.2 Asia-Pacific Neoantigen Cancer Vaccine Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Neoantigen Cancer Vaccine Market Size by Region (2019-2024)
8.4 Asia-Pacific Neoantigen Cancer Vaccine Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Neoantigen Cancer Vaccine Market Size (2019-2030)
9.2 Latin America Neoantigen Cancer Vaccine Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Neoantigen Cancer Vaccine Market Size by Country (2019-2024)
9.4 Latin America Neoantigen Cancer Vaccine Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Neoantigen Cancer Vaccine Market Size (2019-2030)
10.2 Middle East & Africa Neoantigen Cancer Vaccine Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Neoantigen Cancer Vaccine Market Size by Country (2019-2024)
10.4 Middle East & Africa Neoantigen Cancer Vaccine Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Detail
11.1.2 Roche Business Overview
11.1.3 Roche Neoantigen Cancer Vaccine Introduction
11.1.4 Roche Revenue in Neoantigen Cancer Vaccine Business (2019-2024)
11.1.5 Roche Recent Development
11.2 Medimmune
11.2.1 Medimmune Company Detail
11.2.2 Medimmune Business Overview
11.2.3 Medimmune Neoantigen Cancer Vaccine Introduction
11.2.4 Medimmune Revenue in Neoantigen Cancer Vaccine Business (2019-2024)
11.2.5 Medimmune Recent Development
11.3 Merck
11.3.1 Merck Company Detail
11.3.2 Merck Business Overview
11.3.3 Merck Neoantigen Cancer Vaccine Introduction
11.3.4 Merck Revenue in Neoantigen Cancer Vaccine Business (2019-2024)
11.3.5 Merck Recent Development
11.4 Advaxis
11.4.1 Advaxis Company Detail
11.4.2 Advaxis Business Overview
11.4.3 Advaxis Neoantigen Cancer Vaccine Introduction
11.4.4 Advaxis Revenue in Neoantigen Cancer Vaccine Business (2019-2024)
11.4.5 Advaxis Recent Development
11.5 Agenus
11.5.1 Agenus Company Detail
11.5.2 Agenus Business Overview
11.5.3 Agenus Neoantigen Cancer Vaccine Introduction
11.5.4 Agenus Revenue in Neoantigen Cancer Vaccine Business (2019-2024)
11.5.5 Agenus Recent Development
11.6 Genocea
11.6.1 Genocea Company Detail
11.6.2 Genocea Business Overview
11.6.3 Genocea Neoantigen Cancer Vaccine Introduction
11.6.4 Genocea Revenue in Neoantigen Cancer Vaccine Business (2019-2024)
11.6.5 Genocea Recent Development
11.7 Gritstone Oncology
11.7.1 Gritstone Oncology Company Detail
11.7.2 Gritstone Oncology Business Overview
11.7.3 Gritstone Oncology Neoantigen Cancer Vaccine Introduction
11.7.4 Gritstone Oncology Revenue in Neoantigen Cancer Vaccine Business (2019-2024)
11.7.5 Gritstone Oncology Recent Development
11.8 Neon Therapeutics
11.8.1 Neon Therapeutics Company Detail
11.8.2 Neon Therapeutics Business Overview
11.8.3 Neon Therapeutics Neoantigen Cancer Vaccine Introduction
11.8.4 Neon Therapeutics Revenue in Neoantigen Cancer Vaccine Business (2019-2024)
11.8.5 Neon Therapeutics Recent Development
11.9 Nouscom
11.9.1 Nouscom Company Detail
11.9.2 Nouscom Business Overview
11.9.3 Nouscom Neoantigen Cancer Vaccine Introduction
11.9.4 Nouscom Revenue in Neoantigen Cancer Vaccine Business (2019-2024)
11.9.5 Nouscom Recent Development
11.10 OSE Immunotherapeutics
11.10.1 OSE Immunotherapeutics Company Detail
11.10.2 OSE Immunotherapeutics Business Overview
11.10.3 OSE Immunotherapeutics Neoantigen Cancer Vaccine Introduction
11.10.4 OSE Immunotherapeutics Revenue in Neoantigen Cancer Vaccine Business (2019-2024)
11.10.5 OSE Immunotherapeutics Recent Development
11.11 Medigene
11.11.1 Medigene Company Detail
11.11.2 Medigene Business Overview
11.11.3 Medigene Neoantigen Cancer Vaccine Introduction
11.11.4 Medigene Revenue in Neoantigen Cancer Vaccine Business (2019-2024)
11.11.5 Medigene Recent Development
11.12 Vaccibody
11.12.1 Vaccibody Company Detail
11.12.2 Vaccibody Business Overview
11.12.3 Vaccibody Neoantigen Cancer Vaccine Introduction
11.12.4 Vaccibody Revenue in Neoantigen Cancer Vaccine Business (2019-2024)
11.12.5 Vaccibody Recent Development
11.13 Brightpath Biotherapeutics
11.13.1 Brightpath Biotherapeutics Company Detail
11.13.2 Brightpath Biotherapeutics Business Overview
11.13.3 Brightpath Biotherapeutics Neoantigen Cancer Vaccine Introduction
11.13.4 Brightpath Biotherapeutics Revenue in Neoantigen Cancer Vaccine Business (2019-2024)
11.13.5 Brightpath Biotherapeutics Recent Development
11.14 Geneos Therapeutics
11.14.1 Geneos Therapeutics Company Detail
11.14.2 Geneos Therapeutics Business Overview
11.14.3 Geneos Therapeutics Neoantigen Cancer Vaccine Introduction
11.14.4 Geneos Therapeutics Revenue in Neoantigen Cancer Vaccine Business (2019-2024)
11.14.5 Geneos Therapeutics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Neoantigen Cancer Vaccine Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Personalized Vaccine
Table 3. Key Players of Off-the-shelf Neovaccines
Table 4. Global Neoantigen Cancer Vaccine Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 5. Global Neoantigen Cancer Vaccine Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Neoantigen Cancer Vaccine Market Size by Region (2019-2024) & (US$ Million)
Table 7. Global Neoantigen Cancer Vaccine Market Share by Region (2019-2024)
Table 8. Global Neoantigen Cancer Vaccine Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 9. Global Neoantigen Cancer Vaccine Market Share by Region (2025-2030)
Table 10. Neoantigen Cancer Vaccine Market Trends
Table 11. Neoantigen Cancer Vaccine Market Drivers
Table 12. Neoantigen Cancer Vaccine Market Challenges
Table 13. Neoantigen Cancer Vaccine Market Restraints
Table 14. Global Neoantigen Cancer Vaccine Revenue by Players (2019-2024) & (US$ Million)
Table 15. Global Neoantigen Cancer Vaccine Market Share by Players (2019-2024)
Table 16. Global Top Neoantigen Cancer Vaccine Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neoantigen Cancer Vaccine as of 2023)
Table 17. Ranking of Global Top Neoantigen Cancer Vaccine Companies by Revenue (US$ Million) in 2023
Table 18. Global 5 Largest Players Market Share by Neoantigen Cancer Vaccine Revenue (CR5 and HHI) & (2019-2024)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Neoantigen Cancer Vaccine Product Solution and Service
Table 21. Date of Enter into Neoantigen Cancer Vaccine Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Neoantigen Cancer Vaccine Market Size by Type (2019-2024) & (US$ Million)
Table 24. Global Neoantigen Cancer Vaccine Revenue Market Share by Type (2019-2024)
Table 25. Global Neoantigen Cancer Vaccine Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 26. Global Neoantigen Cancer Vaccine Revenue Market Share by Type (2025-2030)
Table 27. Global Neoantigen Cancer Vaccine Market Size by Application (2019-2024) & (US$ Million)
Table 28. Global Neoantigen Cancer Vaccine Revenue Market Share by Application (2019-2024)
Table 29. Global Neoantigen Cancer Vaccine Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 30. Global Neoantigen Cancer Vaccine Revenue Market Share by Application (2025-2030)
Table 31. North America Neoantigen Cancer Vaccine Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 32. North America Neoantigen Cancer Vaccine Market Size by Country (2019-2024) & (US$ Million)
Table 33. North America Neoantigen Cancer Vaccine Market Size by Country (2025-2030) & (US$ Million)
Table 34. Europe Neoantigen Cancer Vaccine Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 35. Europe Neoantigen Cancer Vaccine Market Size by Country (2019-2024) & (US$ Million)
Table 36. Europe Neoantigen Cancer Vaccine Market Size by Country (2025-2030) & (US$ Million)
Table 37. Asia-Pacific Neoantigen Cancer Vaccine Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 38. Asia-Pacific Neoantigen Cancer Vaccine Market Size by Region (2019-2024) & (US$ Million)
Table 39. Asia-Pacific Neoantigen Cancer Vaccine Market Size by Region (2025-2030) & (US$ Million)
Table 40. Latin America Neoantigen Cancer Vaccine Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 41. Latin America Neoantigen Cancer Vaccine Market Size by Country (2019-2024) & (US$ Million)
Table 42. Latin America Neoantigen Cancer Vaccine Market Size by Country (2025-2030) & (US$ Million)
Table 43. Middle East & Africa Neoantigen Cancer Vaccine Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 44. Middle East & Africa Neoantigen Cancer Vaccine Market Size by Country (2019-2024) & (US$ Million)
Table 45. Middle East & Africa Neoantigen Cancer Vaccine Market Size by Country (2025-2030) & (US$ Million)
Table 46. Roche Company Detail
Table 47. Roche Business Overview
Table 48. Roche Neoantigen Cancer Vaccine Product
Table 49. Roche Revenue in Neoantigen Cancer Vaccine Business (2019-2024) & (US$ Million)
Table 50. Roche Recent Development
Table 51. Medimmune Company Detail
Table 52. Medimmune Business Overview
Table 53. Medimmune Neoantigen Cancer Vaccine Product
Table 54. Medimmune Revenue in Neoantigen Cancer Vaccine Business (2019-2024) & (US$ Million)
Table 55. Medimmune Recent Development
Table 56. Merck Company Detail
Table 57. Merck Business Overview
Table 58. Merck Neoantigen Cancer Vaccine Product
Table 59. Merck Revenue in Neoantigen Cancer Vaccine Business (2019-2024) & (US$ Million)
Table 60. Merck Recent Development
Table 61. Advaxis Company Detail
Table 62. Advaxis Business Overview
Table 63. Advaxis Neoantigen Cancer Vaccine Product
Table 64. Advaxis Revenue in Neoantigen Cancer Vaccine Business (2019-2024) & (US$ Million)
Table 65. Advaxis Recent Development
Table 66. Agenus Company Detail
Table 67. Agenus Business Overview
Table 68. Agenus Neoantigen Cancer Vaccine Product
Table 69. Agenus Revenue in Neoantigen Cancer Vaccine Business (2019-2024) & (US$ Million)
Table 70. Agenus Recent Development
Table 71. Genocea Company Detail
Table 72. Genocea Business Overview
Table 73. Genocea Neoantigen Cancer Vaccine Product
Table 74. Genocea Revenue in Neoantigen Cancer Vaccine Business (2019-2024) & (US$ Million)
Table 75. Genocea Recent Development
Table 76. Gritstone Oncology Company Detail
Table 77. Gritstone Oncology Business Overview
Table 78. Gritstone Oncology Neoantigen Cancer Vaccine Product
Table 79. Gritstone Oncology Revenue in Neoantigen Cancer Vaccine Business (2019-2024) & (US$ Million)
Table 80. Gritstone Oncology Recent Development
Table 81. Neon Therapeutics Company Detail
Table 82. Neon Therapeutics Business Overview
Table 83. Neon Therapeutics Neoantigen Cancer Vaccine Product
Table 84. Neon Therapeutics Revenue in Neoantigen Cancer Vaccine Business (2019-2024) & (US$ Million)
Table 85. Neon Therapeutics Recent Development
Table 86. Nouscom Company Detail
Table 87. Nouscom Business Overview
Table 88. Nouscom Neoantigen Cancer Vaccine Product
Table 89. Nouscom Revenue in Neoantigen Cancer Vaccine Business (2019-2024) & (US$ Million)
Table 90. Nouscom Recent Development
Table 91. OSE Immunotherapeutics Company Detail
Table 92. OSE Immunotherapeutics Business Overview
Table 93. OSE Immunotherapeutics Neoantigen Cancer Vaccine Product
Table 94. OSE Immunotherapeutics Revenue in Neoantigen Cancer Vaccine Business (2019-2024) & (US$ Million)
Table 95. OSE Immunotherapeutics Recent Development
Table 96. Medigene Company Detail
Table 97. Medigene Business Overview
Table 98. Medigene Neoantigen Cancer Vaccine Product
Table 99. Medigene Revenue in Neoantigen Cancer Vaccine Business (2019-2024) & (US$ Million)
Table 100. Medigene Recent Development
Table 101. Vaccibody Company Detail
Table 102. Vaccibody Business Overview
Table 103. Vaccibody Neoantigen Cancer Vaccine Product
Table 104. Vaccibody Revenue in Neoantigen Cancer Vaccine Business (2019-2024) & (US$ Million)
Table 105. Vaccibody Recent Development
Table 106. Brightpath Biotherapeutics Company Detail
Table 107. Brightpath Biotherapeutics Business Overview
Table 108. Brightpath Biotherapeutics Neoantigen Cancer Vaccine Product
Table 109. Brightpath Biotherapeutics Revenue in Neoantigen Cancer Vaccine Business (2019-2024) & (US$ Million)
Table 110. Brightpath Biotherapeutics Recent Development
Table 111. Geneos Therapeutics Company Detail
Table 112. Geneos Therapeutics Business Overview
Table 113. Geneos Therapeutics Neoantigen Cancer Vaccine Product
Table 114. Geneos Therapeutics Revenue in Neoantigen Cancer Vaccine Business (2019-2024) & (US$ Million)
Table 115. Geneos Therapeutics Recent Development
Table 116. Research Programs/Design for This Report
Table 117. Key Data Information from Secondary Sources
Table 118. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Neoantigen Cancer Vaccine Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Neoantigen Cancer Vaccine Market Share by Type: 2023 VS 2030
Figure 3. Personalized Vaccine Features
Figure 4. Off-the-shelf Neovaccines Features
Figure 5. Global Neoantigen Cancer Vaccine Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 6. Global Neoantigen Cancer Vaccine Market Share by Application: 2023 VS 2030
Figure 7. Hospital Case Studies
Figure 8. Clinic Case Studies
Figure 9. Others Case Studies
Figure 10. Neoantigen Cancer Vaccine Report Years Considered
Figure 11. Global Neoantigen Cancer Vaccine Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 12. Global Neoantigen Cancer Vaccine Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 13. Global Neoantigen Cancer Vaccine Market Share by Region: 2023 VS 2030
Figure 14. Global Neoantigen Cancer Vaccine Market Share by Players in 2023
Figure 15. Global Top Neoantigen Cancer Vaccine Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neoantigen Cancer Vaccine as of 2023)
Figure 16. The Top 10 and 5 Players Market Share by Neoantigen Cancer Vaccine Revenue in 2023
Figure 17. North America Neoantigen Cancer Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 18. North America Neoantigen Cancer Vaccine Market Share by Country (2019-2030)
Figure 19. United States Neoantigen Cancer Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 20. Canada Neoantigen Cancer Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Europe Neoantigen Cancer Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Europe Neoantigen Cancer Vaccine Market Share by Country (2019-2030)
Figure 23. Germany Neoantigen Cancer Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. France Neoantigen Cancer Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. U.K. Neoantigen Cancer Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Italy Neoantigen Cancer Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Russia Neoantigen Cancer Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Nordic Countries Neoantigen Cancer Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Asia-Pacific Neoantigen Cancer Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Asia-Pacific Neoantigen Cancer Vaccine Market Share by Region (2019-2030)
Figure 31. China Neoantigen Cancer Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Japan Neoantigen Cancer Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. South Korea Neoantigen Cancer Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Southeast Asia Neoantigen Cancer Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. India Neoantigen Cancer Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Australia Neoantigen Cancer Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Latin America Neoantigen Cancer Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Latin America Neoantigen Cancer Vaccine Market Share by Country (2019-2030)
Figure 39. Mexico Neoantigen Cancer Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Brazil Neoantigen Cancer Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Middle East & Africa Neoantigen Cancer Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Middle East & Africa Neoantigen Cancer Vaccine Market Share by Country (2019-2030)
Figure 43. Turkey Neoantigen Cancer Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Saudi Arabia Neoantigen Cancer Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Roche Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2019-2024)
Figure 46. Medimmune Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2019-2024)
Figure 47. Merck Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2019-2024)
Figure 48. Advaxis Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2019-2024)
Figure 49. Agenus Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2019-2024)
Figure 50. Genocea Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2019-2024)
Figure 51. Gritstone Oncology Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2019-2024)
Figure 52. Neon Therapeutics Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2019-2024)
Figure 53. Nouscom Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2019-2024)
Figure 54. OSE Immunotherapeutics Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2019-2024)
Figure 55. Medigene Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2019-2024)
Figure 56. Vaccibody Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2019-2024)
Figure 57. Brightpath Biotherapeutics Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2019-2024)
Figure 58. Geneos Therapeutics Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2019-2024)
Figure 59. Bottom-up and Top-down Approaches for This Report
Figure 60. Data Triangulation
Figure 61. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
